Recent development and use of inhibitors of ERK-signaling alone or in combination with revolutionary immune checkpoint inhibitors (ICI) targeting the receptors of cytotoxic T-lymphocyte-associated 4 (CTLA4) and programmed death-1 (PD1) proteins significantly improved survival of cancer patients [52]. This evidence concerns the gene CTLA4 and cancer.